VIVANI
Dead / Abandoned — Abandoned — incomplete response (as of 04 Dec 2025)
What this means for you
This application is over — abandoned 20 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97381998
- Mark type
- Stylized text
- Filed
- 26 Apr 2022
- Published for opposition
- 20 Jun 2023
- Abandoned
- 20 Oct 2025
- Attorney of record
- Scott B. Dunbar
Goods and services
- Class 001 — Chemicals: Nanoporous membranes used in drug delivery devices for controlling the rate of release of the subject therapeutic compound by selecting nano-pores slightly larger than the molecular diameter of the therapeutic compound; Nanoporous membranes used for controlling the rate of release of the subject therapeutic compound by selecting nano-pores slightly larger than the molecular diameter of the therapeutic compound that control the amount and rate of drug released from a drug implant where the drug reservoir dictates the duration of therapy delivered from the drug implant
- Class 005 — Pharmaceuticals: Implantable drug delivery devices having a drug reservoir filled with pharmaceutical preparations and a nanoporous membrane for improving medication adherence in the treatment of chronic disease, in particular, metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy; Implantable drug delivery devices having a drug reservoir and a nanoporous membrane sold preloaded with a therapeutic agent, namely, an injectable device for time release of the therapeutic agent for improving medication adherence in the treatment of chronic disease, in particular, metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy
- Class 010 — Medical apparatus: Nanoporous membranes used in drug delivery devices for improving medication adherence in the treatment of chronic disease, in particular, metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy; miniature long-term drug implants utilizing proprietary implantable drug delivery technology; nanoporous membranes used for improving medication adherence in the treatment of chronic disease, in particular, metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy that control the amount and rate of drug released from a drug implant where the drug reservoir dictates the duration of therapy delivered from the drug implant for treatment of metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy, and other diseases treated with small drug molecules; Electrotherapy medical devices for electrical nerve stimulation and recording, namely, neurostimulation devices, stimulating and recording electrode implants, visual prostheses and visual cortical implants; Cortical electrodes integrally attached to implantable cortical stimulators and other systems, namely, electrodes, stimulators, headpieces, and wearable video processors for the treatment of blindness; Surgical apparatus and instruments for the treatment of blindness; Medical apparatus and instruments for use in surgery for the treatment of blindness; Medical devices for the treatment of blindness
Owner
- VIVANI MEDICAL, INC., ALAMEDA, CA, US
- Second Sight Medical Products, Inc., Valenica, CA, US
- Second Sight Medical Products, Inc., Sylmar, CA, US
Prosecution history
- 16 Jan 2026 — TEAS PETITION TO DIRECTOR RECEIVED
- 04 Dec 2025 — ABANDONMENT NOTICE E-MAILED - INCOMPLETE RESPONSE
- 20 Oct 2025 — ABANDONMENT - INCOMPLETE RESPONSE
- 28 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 28 Nov 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 28 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 28 Nov 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 30 Oct 2025 — NOTIFICATION OF SUBSEQUENT FINAL EMAILED
- 30 Oct 2025 — CONTINUATION OF FINAL REFUSAL E-MAILED
- 30 Oct 2025 — SU - ACTION CONTINUING FINAL - WRITTEN
- 17 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Oct 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED